Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1967 1
1968 1
1969 2
1970 1
1973 1
1977 2
1978 3
1979 2
1980 1
1981 1
1982 4
1983 5
1984 6
1985 8
1986 7
1987 7
1988 10
1989 4
1990 7
1991 6
1992 6
1993 4
1994 5
1995 9
1996 12
1997 10
1998 11
1999 14
2000 16
2001 16
2002 19
2003 20
2004 22
2005 8
2006 7
2007 11
2008 8
2009 7
2010 13
2011 21
2012 21
2013 13
2014 11
2015 25
2016 21
2017 23
2018 28
2019 26
2020 19
2021 30
2022 22
2023 21

Text availability

Article attribute

Article type

Publication date

Search Results

532 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: saji s. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Mittendorf EA, et al. Among authors: saji s. Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20. Lancet. 2020. PMID: 32966830 Clinical Trial.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: saji s. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M. Turner N, et al. Among authors: saji s. Breast Cancer Res Treat. 2022 Feb;191(3):565-576. doi: 10.1007/s10549-021-06450-x. Epub 2021 Dec 3. Breast Cancer Res Treat. 2022. PMID: 34860318 Free PMC article. Clinical Trial.
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M. Ueno T, et al. Among authors: saji s. BMC Med. 2022 Apr 25;20(1):136. doi: 10.1186/s12916-022-02332-1. BMC Med. 2022. PMID: 35462552 Free PMC article.
Early breast cancer.
Suzuki T, Toi M, Saji S, Horiguchi K, Aruga T, Suzuki E, Horiguchi S, Funata N, Karasawa K, Kamata N. Suzuki T, et al. Among authors: saji s. Int J Clin Oncol. 2006 Apr;11(2):108-19. doi: 10.1007/s10147-006-0564-7. Int J Clin Oncol. 2006. PMID: 16622745 Review.
Ectopic uterine cervical ripening dilator.
Hasegawa J, Nishimura Y, Saji S. Hasegawa J, et al. Among authors: saji s. J Med Ultrason (2001). 2023 Sep 16. doi: 10.1007/s10396-023-01361-4. Online ahead of print. J Med Ultrason (2001). 2023. PMID: 37715881 No abstract available.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Saji S, et al. Lancet Oncol. 2022 May;23(5):636-649. doi: 10.1016/S1470-2045(22)00196-6. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405087 Clinical Trial.
Genomic tumor evolution of breast cancer.
Sato F, Saji S, Toi M. Sato F, et al. Among authors: saji s. Breast Cancer. 2016 Jan;23(1):4-11. doi: 10.1007/s12282-015-0617-8. Epub 2015 May 22. Breast Cancer. 2016. PMID: 25998191 Review.
532 results